Skip to main contentAI and Advanced
/
DRREDDY · NSEMarket ticker unavailable · configure an authorised index feed
DR
NSE · Equity shares · Biotechnology & Drugs-5.00 · -0.44%
Dr Reddy's Laboratories DRREDDY
NSE:INR 1,140
BSE:INR 1,175
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for DRREDDY
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 1,145
Day rangeINR 1,133.9 — INR 1,149.9
52-week rangeINR 1,130 — INR 1,414.9
Volume11.21 L
Market cap98,069.82
P/E35.07
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)33,700.2
Net Income (INR Cr)4,196
Rev Growth (5 Year %)12.09
EPS Growth (5 Year %)16.87
P/E Ratio35.07
EPS51.25
Research path: Interpret Dr Reddy's Laboratories's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
DRREDDYDr Reddy's Laboratories1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 58,123.4 | 49,426.6 | 38,863.8 |
| Accumulated Depreciation Total | -10,296.4 | -9,202.9 | -9,258.7 |
| Cash Equivalents | 234.9 | 250.7 | 260 |
| Other Liabilities Total | 378.1 | 275.2 | 337.9 |
| Accrued Expenses | 3,253.7 | 3,041 | 2,971.1 |
| Long Term Debt | 0 | 380 | 380 |
| Common Stock Total | 83.5 | 83.4 | 83.4 |
| Other Equity Total | 916.4 | 189.1 | 196.9 |
| Other Current Assets Total | 411.7 | 294.6 | 241 |
| Prepaid Expenses | 207.5 | 188.3 | 194.7 |
| Total Assets | 58,123.4 | 49,426.6 | 38,863.8 |
| Current Portof LT Debt/Capital Leases | 220.3 | 85.7 | 130.7 |
| Additional Paid-In Capital | 878.4 | 855.3 | 818.6 |
| Cash | 1,285.6 | 1,199.7 | 435 |
| Total Equity | 37,891.5 | 33,549.6 | 28,254.8 |
| Long Term Investments | 1,662.8 | 1,532.9 | 572 |
| Retained Earnings(Accumulated Deficit) | 36,194.7 | 32,648.2 | 27,255 |
| Treasury Stock-Common | -181.5 | -226.4 | -99.1 |
| Total Common Shares Outstanding | 83.27 | 83.2 | 83.26 |
| Property/Plant/Equipment Total-Gross | 21,834.4 | 18,900.7 | 16,858.4 |
| Tangible Book Valueper Share Common Eq | 311.11 | 271.1 | 288.35 |
| Goodwill Net | 1,479.7 | 1,313.9 | 550.1 |
| Total Liabilities | 20,231.9 | 15,877 | 10,609 |
| Total Debt | 7,734.1 | 4,676.6 | 2,002 |
| Short Term Investments | 7,388.2 | 4,325.5 | 7,436.3 |
| Cashand Short Term Investments | 8,908.7 | 5,775.9 | 8,131.3 |
| Total Receivables Net | 12,413.9 | 11,070.3 | 9,883.1 |
| Notes Payable/Short Term Debt | 6,293.5 | 3,804.5 | 1,272.3 |
| Deferred Income Tax | 1,546.7 | 1,403.8 | 84.1 |
| Accounts Receivable-Trade Net | 10,123.4 | 9,042 | 8,029.8 |
| Property/Plant/Equipment Total-Net | 11,538 | 9,697.8 | 7,599.7 |
| Minority Interest | 339.4 | 377.8 | Not available |
| Total Current Liabilities | 16,747.4 | 13,033.8 | 9,588 |
| Total Inventory | 8,237.5 | 7,689 | 6,355.2 |
| Accounts Payable | 3,037.9 | 2,647.8 | 2,614.4 |
| Other Currentliabilities Total | 3,942 | 3,454.8 | 2,599.5 |
| Total Long Term Debt | 1,220.3 | 786.4 | 599 |
| Intangibles Net | 10,505.8 | 9,680.3 | 3,695.1 |
| Other Long Term Assets Total | 2,341.6 | 1,917.2 | 1,174.5 |
| Note Receivable-Long Term | 416.2 | 266.4 | 467.1 |
| Total Current Assets | 30,179.3 | 25,018.1 | 24,805.3 |
| Capital Lease Obligations | 1,220.3 | 406.4 | 219 |
Fundamentals
Valuation and ratios
Growth
Debt 5Yr CAGR %20.61
Margins
Operating Margin 12m9.09
Operating Margin 5y Avg18.16
Net Profit Margin 12m9.58
Net Profit Margin 5y15.75
Yield
Dividend Yield %0.68
Valuation
Price to Sale Ratio2.91
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk26.14
Analyst consensus
ConsensusHold
Consensus score2.97
Analyst opinions38
Strong Sell count4
Sell count10
Hold count10
Buy count9
Strong Buy count5
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 26.64%
- FII
- 20.67%
- MF
- 13.16%
- Other
- 39.53%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Dr. Reddy's Laboratories rallies Thursday, outperforms market - MarketWatchMarket news · 4 Jun 2026, 4:00 pm
Dr. Reddy's Laboratories rallies Thursday, outperforms market MarketWatch
Q&A: Dr. Reddy's CEO on Generic Semaglutide and the GLP-1 Market Ahead - Pharmaceutical CommerceMarket news · 3 Jun 2026, 8:27 pm
Q&A: Dr. Reddy's CEO on Generic Semaglutide and the GLP-1 Market Ahead Pharmaceutical Commerce
Dr. Reddy’s (NYSE: RDY) schedules June 2026 investor conferences in Mumbai and Hyderabad - Stock TitanMarket news · 3 Jun 2026, 4:01 pm
Dr. Reddy’s (NYSE: RDY) schedules June 2026 investor conferences in Mumbai and Hyderabad Stock Titan
Dr. Reddy's Laboratories falls Wednesday, underperforms competitors - MarketWatchMarket news · 3 Jun 2026, 4:00 pm
Dr. Reddy's Laboratories falls Wednesday, underperforms competitors MarketWatch
Dr. Reddy's management to meet investors on June 9-10 - scanx.tradeMarket news · 3 Jun 2026, 12:23 pm
Dr. Reddy's management to meet investors on June 9-10 scanx.trade
Dr. Reddy’s (NYSE: RDY) says DOJ and SEC close FCPA probes without enforcement - Stock TitanMarket news · 2 Jun 2026, 4:51 pm
Dr. Reddy’s (NYSE: RDY) says DOJ and SEC close FCPA probes without enforcement Stock Titan
Corporate actions
Events
- annual General MeetingAGM
- board MeetingsQuarterly Results
- dividendRs.8.0000 per share(800%)Final Dividend
- board MeetingsAudited Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.8.0000 per share(800%)Final Dividend
Rusaka Markets Community
Discussion and sentiment for Dr Reddy's Laboratories
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- DRREDDY
- BSE Code
- 500124
Questions
Stock FAQ
What is the symbol and ISIN of Dr Reddy's Laboratories?
Dr Reddy's Laboratories has the symbol DRREDDY and ISIN - INE089A01031.
What is the current price of Dr Reddy's Laboratories?
Dr Reddy's Laboratories is currently trading at INR 1,140.00.
What are the year high and year low of Dr Reddy's Laboratories?
Dr Reddy's Laboratories has a year high of INR 1,414.90 and a year low of INR 1,130.00.
What is the market capitalization of Dr Reddy's Laboratories?
Dr Reddy's Laboratories has a market capitalization of INR 98,069.82 crore.
What is the P/E ratio of Dr Reddy's Laboratories?
Dr Reddy's Laboratories has a P/E ratio of 35.07.
What is the dividend yield of Dr Reddy's Laboratories?
Dr Reddy's Laboratories has a dividend yield of 0.68%.
How is the financial performance of Dr Reddy's Laboratories based on revenue, net income, and EPS?
Dr Reddy's Laboratories has revenue of INR 33,700.20 crore, net income of INR 4,196.00 crore, and EPS of INR 41.56.
What is the book value of Dr Reddy's Laboratories?
Dr Reddy's Laboratories has a book value of NA.
What is the debt-to-equity ratio of Dr Reddy's Laboratories?
Dr Reddy's Laboratories has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Dr Reddy's Laboratories?
Dr Reddy's Laboratories has a price-to-book ratio of NA and a price-to-sales ratio of 2.91.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.